Holding(s) in Company
Â
Â
Â
TR-1: Standard form for notification of major shareholdingsÂ
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
           Â
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii | Arrow Global Group PLC | ||
2 Reason for the notification (please tick the appropriate box or boxes): | |||
An acquisition or disposal of voting rights | Â | ||
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | Â | ||
An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | X | ||
An event changing the breakdown of voting rights | Â | ||
Other (please specify): |  | ||
3. Full name of person(s) subject to the notification obligation: iii | Kairos Investment Management Limited as agent for: Kairos Pegasus Fund Ltd, ("PEG SA") Kairos International Sicav - Pegasus UCITS ("KIS PEG")  | ||
4. Full name of shareholder(s) Â Â (if different from 3.):iv | Kairos Pegasus Fund Ltd, ("PEG SA") Kairos International Sicav - Pegasus UCITS ("KIS PEG") Â | ||
5. Date of the transaction and date on which the threshold is crossed or reached: v | 15.05.17 | ||
6. Date on which issuer notified: | 30.10.18 | ||
7. Threshold(s) that is/are crossed or reached: vi, vii | GOING BELOW 3% | ||
 |  |  |  |
Â
8. Notified details: | |||||||
A: Voting rights attached to shares viii, ix | |||||||
Class/type of shares  if possible using the ISIN CODE | Situation previous to the triggering transaction | Resulting situation after the triggering transaction | |||||
Number of Shares | Number of Voting Rights | Number of shares | Number of voting rights | % of voting rights x | |||
Direct | Direct xi | Indirect xii | Direct | Indirect | |||
 GB00BDGTXM 47 | 107000 | 107000 | 107000 | 107000 | 0.00 | 0.06 | 0.00 |
Â
B: Qualifying Financial Instruments | Â | Â | ||
Resulting situation after the triggering transaction | Â | Â | ||
Type of financial instrument | Expiration date xiii | Exercise/Â Conversion Period xiv | Number of voting rights that may be acquired if the instrument is exercised/ converted. | % of voting rights |
N/A | N/A | N/A | N/A | N/A |
Â
C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
Resulting situation after the triggering transaction | ||||||
Type of financial instrument | Exercise price | Expiration date xvii | Exercise/ Conversion period xviii | Number of voting rights instrument refers to  | % of voting rights xix, xx   | |
  Contract for difference  Contract for difference  |   N/A  N/A |  07.06.18   15.01.26 |       |   4,237,457   822,139  | Nominal | Delta |
  2.42%   0.47%    |  |
Â
Â
Total (A+B+C) | Â |
Number of voting rights | Percentage of voting rights |
5,166,596 | 2.95% |
Â
Â
9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi |
 As at 15.05.17, KIML acting as agent for KISPEG and PEG SA held 3.02% interest in Arrow Global. Split: Ordinary Shares with voting rights 107,000 = 0.06% KIS Peg Swap held with Goldman Sachs - Expiry 15.01.26  822,139 = 2.48% PEG SA Swap held with Morgan Stanley - Expiry 07.06.18  4,237,457 = 0.48% KIS PEG   As at 15.10.18 (date of notification), KIML acting as agent for KISPEG and PEG SA does not hold any interest in Arrow Global, As such it remains BELOW 3% at 0.00%,      |
Â
Proxy Voting: | Â |
10. Name of the proxy holder: | Kairos Investment Management Limited |
11. Number of voting rights proxy holder will cease to hold: | N/A |
12. Date on which proxy holder will cease to hold voting rights: | N/A |
Â
 13. Additional information: |  None |
14. Contact name: | Sophie Howard |
15. Contact telephone number: | 020 7398 3060 |
Â
Â
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.